Physician profile
William A Manus
NPI 1902898232
$1,640.58
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $156 · 2021: $437 · 2022: $185 · 2023: $257 · 2024: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $514.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $201.64 | 2019-2022 | |
| Glaxosmithkline, LLC. | $177.55 | 2022-2024 | Bexsero, Shingrix, Arexvy |
| Novo Nordisk INC | $150.31 | 2019-2023 | Saxenda, Wegovy |
| Sanofi-Aventis U.S. LLC | $129.66 | 2019-2024 | |
| Corcept Therapeutics | $125.56 | 2021-2024 | Korlym |
| Amarin Pharma, INC. | $99.20 | 2019-2021 | |
| Astellas Pharma US INC | $97.35 | 2023-2024 | Veozah |
| Esperion Therapeutics, INC. | $91.46 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $75.33 | 2022-2024 | Rexulti |
| Baxter Healthcare | $75.14 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Eisai INC. | $54.94 | 2020-2021 | |
| Abbvie INC. | $54.01 | 2020-2022 | |
| Abbott Laboratories | $41.35 | 2020-2023 | Freestyle Libre 3 |
| Pfizer INC. | $25.87 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $24.05 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $22.79 | 2024 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.13 | 2021 | |
| Jazz Pharmaceuticals INC. | $17.62 | 2022 | |
| Dexcom, INC. | $16.64 | 2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.01 | 2020 | |
| Sanofi Pasteur INC. | $15.74 | 2019 | |
| Ironwood Pharmaceuticals, INC | $15.26 | 2023 | Linzess |
| Xeris Pharmaceuticals, INC. | $14.61 | 2021 | |
| Exact Sciences Corporation | $13.63 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $13.10 | 2019 | |
| Lilly USA, LLC | $12.91 | 2019 | |
| Genentech USA, INC. | $12.91 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.34 | 2021 | |
| Nevro Corp. | $11.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Manus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.